Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Copeland

Showing results (371-380 of 449) with videos related to

Pageof 45
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 4, 2013
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Floor J Backes, Debra L Richardson, Georgia A McCann, et al.
Gynecologic Oncology|February 6, 2019
Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancerMegan L Hutchcraft, Blair Smith, Eric M McLaughlin, et al.
Human Pathology|August 7, 2004
Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative imagesJeffrey D Seidman, Robert A Soslow, Russell Vang, et al.
Gynecologic Oncology|April 24, 2022
Practice changing cervical cancer clinical trialsBhavana Pothuri, Ramez N Eskander, Leslie M Randall, et al.
Gynecologic Oncology|January 30, 2013
Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage diseaseGeorgia A McCann, Christina E Boutsicaris, Megan M Preston, et al.
Gynecologic Oncology|August 2, 2014
Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?Floor J Backes, Caroline C Billingsley, Douglas D Martin, et al.
International Journal of Radiation Oncology, Biology, Physics|April 1, 1988
Hyperfractionated split-course whole abdominal radiotherapy for ovarian carcinoma: tolerance and toxicityJ S Kong, L J Peters, J T Wharton, et al.
Gynecologic Oncology|November 10, 2012
The impact of close surgical margins after radical hysterectomy for early-stage cervical cancerGeorgia A McCann, Susanne K Taege, Christina E Boutsicaris, et al.
Cancer|December 15, 1985
Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamideD M Gershenson, L J Copeland, J J Kavanagh, et al.
Gynecologic Oncology|February 15, 2011
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancerDavid M O'Malley, Debra L Richardson, Patrick S Rheaume, et al.
Pageof 45

Showing results (371-380 of 449) with videos related to

Sort By:
Pageof 45
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 4, 2013
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Floor J Backes, Debra L Richardson, Georgia A McCann, et al.
Gynecologic Oncology|February 6, 2019
Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancerMegan L Hutchcraft, Blair Smith, Eric M McLaughlin, et al.
Human Pathology|August 7, 2004
Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative imagesJeffrey D Seidman, Robert A Soslow, Russell Vang, et al.
Gynecologic Oncology|April 24, 2022
Practice changing cervical cancer clinical trialsBhavana Pothuri, Ramez N Eskander, Leslie M Randall, et al.
Gynecologic Oncology|January 30, 2013
Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage diseaseGeorgia A McCann, Christina E Boutsicaris, Megan M Preston, et al.
Gynecologic Oncology|August 2, 2014
Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?Floor J Backes, Caroline C Billingsley, Douglas D Martin, et al.
International Journal of Radiation Oncology, Biology, Physics|April 1, 1988
Hyperfractionated split-course whole abdominal radiotherapy for ovarian carcinoma: tolerance and toxicityJ S Kong, L J Peters, J T Wharton, et al.
Gynecologic Oncology|November 10, 2012
The impact of close surgical margins after radical hysterectomy for early-stage cervical cancerGeorgia A McCann, Susanne K Taege, Christina E Boutsicaris, et al.
Cancer|December 15, 1985
Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamideD M Gershenson, L J Copeland, J J Kavanagh, et al.
Gynecologic Oncology|February 15, 2011
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancerDavid M O'Malley, Debra L Richardson, Patrick S Rheaume, et al.
Pageof 45